{"id":"W4361958339","doi":"10.1158/1078-0432.c.6530591.v1","title":"Data from Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Adverse effect; Antibody; Melanoma; Gastroenterology; Colorectal cancer; Cancer; Oncology; Immunology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005540112,0.001261787,0.002094948,0.0004406298,0.0005953075,0.001389638,0.0007773234,0.001226029,0.006993426],"category_scores_gemma":[0.005162945,0.0004848186,0.002134608,0.0007868437,0.0005497498,0.001294952,0.0003970893,0.002862168,0.002002705],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009312889,"about_ca_system_score_gemma":0.001925339,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001211852,"about_ca_topic_score_gemma":0.002376358,"domain_scores_codex":[0.9980928,0.0009779448,0.0002085476,0.0002190618,0.0003585666,0.0001429837],"domain_scores_gemma":[0.9937218,0.002561734,0.001337759,0.00071982,0.0006511192,0.001007777],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.6407698,0.01777681,0.03159937,0.004443225,0.007562291,0.0004309819,0.0002993427,0.01815245,0.02188111,0.0009660867,0.06850594,0.1876126],"study_design_scores_gemma":[0.4916945,0.2577927,0.1178822,0.0008095805,0.009756879,0.001813207,0.0002375203,0.00962444,0.01912997,0.002619205,0.08841737,0.0002223136],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"dataset","genre_scores_codex":[0.7887553,0.01583281,0.008775217,0.003731541,0.0006596326,0.008146323,0.1384488,0.0007151642,0.03493511],"genre_scores_gemma":[0.8606202,0.004696931,0.004187944,0.004119632,0.0002758537,0.005858233,0.1114733,0.0001841181,0.008583774],"genre_candidate":"dataset","genre_consensus":null,"teacher_disagreement_score":0.006993426,"threshold_uncertainty_score":0.02929932,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1847133341655085,"score_gpt":0.510112216982763,"score_spread":0.3253988828172545,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}